Treatment of bleeding in hemophilia

	Hemophilia A	Hemophilia B
Major/severe bleeding^* Raise factor level to 80 to 100%	Factor VIII dose of approximately 50 units/kg	Factor IX dose of approximately 100 to 140 units/kg
Hemarthrosis Raise factor level to 40 to 50%	Factor VIII dose of approximately 25 units/kg	Factor IX dose of approximately 50 to 70 units/kg

This table is a general guide and does not replace clinical judgment in determining the severity of bleeding, risk of morbidity, factor dosing, and need for other treatments.

Joint bleeding may require higher dosing, especially in the hips, wrists, or any target joint or joint bleeding that does not respond to therapy at home.
Mucosal bleeding can be treated with an antifibrinolytic agent or local hemostatic therapies concomitantly with factor infusion.
Patients with mild hemophilia A and minor bleeding may be treated with DDAVP if they have a previously demonstrated response.
Patients with inhibitors may require a bypassing agent such as recombinant activated factor VII (rFVIIa) or FEIBA.
Do not combine FEIBA with emicizumab or an antifibrinolytic agent.

Refer to UpToDate for additional information about management of bleeding in patients with hemophilia.

FEIBA: factor eight inhibitor bypassing agent.

* Examples of major/severe bleeding include:

Bleeding affecting the central nervous system or eyes, airway, hip, deep muscle with neurovascular injury, or abdomen.
Bleeding that cannot be controlled with local therapies.
Bleeding causing anemia or necessitating transfusion.

Graphic 110820 Version 2.0

خرید پکیج

Treatment of bleeding in hemophilia